OncoMatch/Clinical Trials/NCT07106723
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Is NCT07106723 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ASCT+CD7-CART for cd7 positive.
Treatment: ASCT+CD7-CART — To evaluate the safety and efficacy of autologous hematopoietic stem cell transfer (ASCT) combined with CD7-CART in the treatment of CD7+ TCL
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD7 expression
Confirmed as tumor cells expressing CD7 by histopathology and/or cytology at the time of screening
Allowed: TP53 deletion
high-risk factors, such as ... TP53 deletion/mutation
Allowed: TP53 mutation
high-risk factors, such as ... TP53 deletion/mutation
Allowed: RAS activating mutation
high-risk factors, such as ... RAS activating mutation
Disease stage
Required: Stage III, IV
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplant
Have a history of autologous/allogeneic hematopoietic stem cell transplantation
Cannot have received: allogeneic hematopoietic stem cell transplant
Have a history of autologous/allogeneic hematopoietic stem cell transplantation
Cannot have received: CAR-T cell therapy
Have used any CAR-T cell products or other genetically modified T-cell therapies
Cannot have received: CD7-targeted therapy
Received CD7-targeted therapy
Lab requirements
Blood counts
INR ≤ 1.5x ULN, aPTT ≤ 1.5x ULN
Kidney function
serum creatinine clearance rate ≥ 30 mL/min
Liver function
ALT and AST ≤ 3x ULN (≤ 5x ULN if due to disease); total serum bilirubin ≤ 2x ULN (≤ 3x ULN for Gilbert's syndrome, direct bilirubin ≤ 1.5x ULN)
Cardiac function
Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal ECG findings; no clinically significant pericardial effusion and pleural effusion
With appropriate organ function: 1) ALT and AST ≤ 3x ULN (≤ 5x ULN if due to disease); 2) Total serum bilirubin ≤ 2x ULN, except for patients with Gilbert's syndrome; patients with Gilbert's syndrome and total bilirubin ≤ 3x ULN and direct bilirubin ≤ 1.5x ULN can be included; 3) Serum creatinine clearance rate ≥ 30 mL/min; 4) INR ≤ 1.5x ULN, and aPTT ≤ 1.5x ULN; 5) Possessing the minimum level of lung reserve, defined as ≤ grade 1 dyspnea (CTCAE v5.0) and non-oxygen-dependent blood oxygen saturation ≥ 92%; 6) Left ventricular ejection fraction ≥ 50% by echocardiography; no clinically significant abnormal electrocardiogram findings; no clinically significant pericardial effusion and pleural effusion.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify